Over 100 Indian-Made Drugs Declared Substandard, NAFDAC Issues Public Alert

The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert following the declaration of over 100 medications as Not of Standard Quality (NSQ) by India’s Central Drugs Standard Control Organization (CDSCO).

According to information received by NAFDAC, these drugs failed quality control tests conducted on samples collected from distribution and sales points across India.

The affected medications were manufactured by 17 pharmaceutical companies, some of which have subsidiaries, business partners, or product distributions in Nigeria.

The companies identified in the CDSCO report include:

1. Abaris Healthcare Pvt Ltd
2. Alencure Biotech Pvt Ltd
3. Eurolife Healthcare Pvt Ltd
4. Health Biotech Ltd
5. HIGGS Healthcare
6. Karnataka Antibiotics & Pharmaceuticals Ltd (KAPL)
7. Laborate Pharmaceuticals India Ltd
8. Legend Industries
9. Martins & Brown Biosciences Pvt Ltd
10. Mascot Health Series Pvt Ltd
11. Micron Pharmaceutical
12. Orison Pharma International
13. Rivpra Formulation Pvt Ltd
14. Sai Parenterals Ltd
15. Symbiosis Pharmaceuticals Pvt Ltd
16. Syncom Formulations (India) Ltd
17. Zee Laboratories Ltd

NAFDAC has urged healthcare professionals, pharmacists, and consumers to exercise caution and vigilance. Suspected cases of substandard or falsified medicines should be reported to the nearest NAFDAC office, via the toll-free number 0800-162-3322, or through email at sf.alert@nafdac.gov.ng.

The agency emphasized its commitment to safeguarding public health and warned that it is actively investigating the local presence of these products.